The Effect of Botulinum Toxin A on Calf Reduction

Type A Botulinum Toxin이 장딴지근 퇴축에 미치는 영향

  • Park, Jung Min (Department of Plastic & Reconstructive Surgery,College of Medicine, Dong-A University) ;
  • Ha, Jae Seong (Department of Plastic & Reconstructive Surgery,College of Medicine, Dong-A University) ;
  • Lee, Keun Cheol (Department of Plastic & Reconstructive Surgery,College of Medicine, Dong-A University) ;
  • Kim, Seok Kwun (Department of Plastic & Reconstructive Surgery,College of Medicine, Dong-A University) ;
  • Lee, Gi Nam (Diagnostic Radiology,College of Medicine, Dong-A University) ;
  • Lee, Myong Jong (Diagnostic Radiology,College of Medicine, Dong-A University) ;
  • Lee, Kun Ho (Nobless Aesthetic Plastic Surgical Clinic)
  • 박정민 (동아대학교 의과대학 성형외과학교실) ;
  • 하재성 (동아대학교 의과대학 성형외과학교실) ;
  • 이근철 (동아대학교 의과대학 성형외과학교실) ;
  • 김석권 (동아대학교 의과대학 성형외과학교실) ;
  • 이기남 (동아대학교 의과대학 진단방사선과학교실) ;
  • 이명종 (동아대학교 의과대학 진단방사선과학교실) ;
  • 이건호 (노블레스 성형외과)
  • Received : 2004.08.23
  • Published : 2005.01.10

Abstract

Botulinum toxin type A is widely used for anti-wrinkling therapy, and correction of the square face. The toxin ultimately prevent the release of membrane-bound acetylcholine at the neuromuscular junction of striated muscles and thus produce chemical denervation and paralysis of the muscles. Our purpose of study is to know if application of botulinum toxin type A on calf reduction is effective, how much dosage is effective, and what are the possible complications. We reviewed data of 30 consecutive patients subjected to calf reduction in Dong-A University Hospital from February 2003 to April 2003. We injected normal saline 2cc on both calves region in 15 control group patients, and the other patients was divided 3 group. Group 1, Group 2, Group 3 was injected 50U, 100U, 150U botulinum toxin A on each calf region and followed up for 6 month. Maximal circumference of calf was not changed in the control group but an average of 0.7 cm reduction was noted in group 1, average 1.34 cm(right calf) and 1.26cm(left calf) in group 2, average 1.44cm(right calf) and 1.58cm(left calf) in group 3. Maximal area of calf was not changed in the control group but average reduction of 12.5%(right calf) and 12.7%(left calf) was obtained in group 1, average 19.4% (right calf) and 19.9%(left calf) in group 2, average 24.8%(right calf) and 21.07%(left calf) in group 3, as measured on CAT scan. Total fat amount and fat amount in the lower extremity was no change in all the groups, but lean body mass was decreased average 1.27%(right calf) and 1.15%(left calf) in group 1, average 3.47%(right calf) and 2.98%(left calf) in group 2, average 3.58%(right calf) and 3.95%(left calf) in group 3. Photography of the preoperative and postoperative 6 month state revealed higher satisfaction in Group 2, 3 compared to Group 1. Use of botulinum toxin type A in calf reduction is a very simple, safe, non-invasive method and effective in terms of calf contouring rather than reduction of calf circumference.

Keywords

References

  1. Keen M, Blitzer A, Aviv J, Binder W, Prystowsky J, Smith H, Brin M: Botulinum toxin A therapy for hyperkinetic facial lines: Results of a double-blind, placebocontrolled study. Plast Reconstr Surg 94: 94, 1994 https://doi.org/10.1097/00006534-199407000-00009
  2. Carruthers J, Carruthers A: Botulinum A exotoxin in clinical ophthalmology. Can J Opthalmol 31: 389, 1996
  3. Shelley WB, Talanin NY, Shelley ED: Botulinum toxin therapy for palmar hyperhidrosis. J Am Acad Dermatol 38: 227, 1998 https://doi.org/10.1016/S0190-9622(98)70242-7
  4. Glogau RG: Botulinum A neurotoxin for axillary hyperhidrosis: No sweat Botox. Dennatol Surg 24: 817, 1998 https://doi.org/10.1016/S1076-0512(98)00077-6
  5. Moore AP, Wood GD: The medical management of masseteric hypertrophy with botulinum toxin type A. British J Oral Maxillofacial Surg 32: 29, 1994 https://doi.org/10.1016/0266-4356(94)90169-4
  6. Simpson LL: Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacal Exp Ther 212: 16, 1980
  7. Simpson LL, Dasgupta BR: Botulinum neurotoxin type E: Studies on mechanism of action and on structure activity relationships. J Pharmacol Exp Ther 224: 135, 1983
  8. Black JD, Dolly JO: Interaction of 125I-labelled botulinum neurotoxins with nerve terminals. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell BioI 103: 521, 1986 https://doi.org/10.1083/jcb.103.2.521
  9. Illouz YG: Surgical remodelling of the silhouette by aspiration lipolysis or selective lipectomy. Aesth Plast Surg 9: 7, 1985 https://doi.org/10.1007/BF01570678
  10. Hwang K, Kim, YJ, Chung IH, Tanaka S, Lee SI: Innervation of calf Muscles in relation to calf reduction. Ann of Plast Surg 50: 517, 2003 https://doi.org/10.1097/01.SAP.0000044364.71359.BC
  11. Park WJ, Lee TH, Shin MS: Calf contouring through gastrocnemius partial tenotomy. J Korean Plast Reconstr Surg 106: 330, 1999
  12. Jankovic J, Schwartz K: Response and imrnunoresistance to botulinum toxin injections. Neurology 45: 1743, 1995 https://doi.org/10.1212/WNL.45.9.1743
  13. Goschel H, Wohlfaqrth K, Frevert J, Dengler R, Bigalke H: Botulinum A toxin therapy: Neutralizing and nonneutralizing antibodies-therapeutic consequence. Exp Neural 147: 96, 1997 https://doi.org/10.1006/exnr.1997.6580
  14. Borodic G, Johnson E, Goodnough M, Schantz E: Botulinum toxin therapy, immunologic resistance and problems with available materials. Neurology 46: 26, 1996 https://doi.org/10.1212/WNL.46.1.26